Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Instil Bio Inc. (TIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: TIL (4-star) is a WEAK-BUY. BUY since 30 days. Profits (11.47%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $118.67
1 Year Target Price $118.67
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 214.61% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 155.08M USD | Price to earnings Ratio - | 1Y Target Price 118.67 |
Price to earnings Ratio - | 1Y Target Price 118.67 | ||
Volume (30-day avg) 4 | Beta 2.28 | 52 Weeks Range 9.70 - 92.00 | Updated Date 07/8/2025 |
52 Weeks Range 9.70 - 92.00 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.59% | Return on Equity (TTM) -44.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 138092674 | Price to Sales(TTM) 55329.79 |
Enterprise Value 138092674 | Price to Sales(TTM) 55329.79 | ||
Enterprise Value to Revenue 43213.95 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 6559930 | Shares Floating 2649948 |
Shares Outstanding 6559930 | Shares Floating 2649948 | ||
Percent Insiders 6.51 | Percent Institutions 80.57 |
Upturn AI SWOT
Instil Bio Inc.
Company Overview
History and Background
Instil Bio Inc. is a biopharmaceutical company focused on developing adoptive cell therapies for the treatment of cancer. Founded in 2018, it went public in 2021. The company aims to use its expertise in tumor-infiltrating lymphocyte (TIL) therapies to address unmet medical needs in cancer treatment.
Core Business Areas
- TIL Therapy Development: Developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors.
- Manufacturing and Process Development: Enhancing the manufacturing process for TIL therapies to improve efficacy and scalability.
- Research and Development: Conducting preclinical and clinical research to discover and develop next-generation TIL therapies.
Leadership and Structure
The company is led by CEO Bronson Moore. The organizational structure includes departments focused on research and development, clinical operations, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- ITIL-168 (Lead Candidate): ITIL-168 is Instil Bio's lead TIL therapy candidate, targeting advanced melanoma. It is currently in clinical trials. There is no public data on the market share or revenue for ITIL-168, as it is still in development. Competitors include Iovance Biotherapeutics (IOVA) and other companies developing cell therapies for melanoma.
- Other TIL Programs: Instil Bio has other TIL therapy programs in preclinical and early clinical development targeting other solid tumors. There is no public data on the market share or revenue for this. Competitors include other cell therapy companies, as well as companies developing traditional cancer treatments.
Market Dynamics
Industry Overview
The cell therapy market is growing rapidly, driven by advances in immunotherapy and personalized medicine. There is significant unmet need for effective treatments for solid tumors.
Positioning
Instil Bio is positioned as a developer of next-generation TIL therapies, with a focus on improving manufacturing and scalability. It aims to address the limitations of first-generation TIL therapies.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to be in the tens of billions of dollars. Instil Bio is positioned to capture a portion of this market with its TIL therapy platform, pending successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary TIL therapy platform
- Experienced management team
- Focus on improving TIL manufacturing
- Pipeline of TIL therapy candidates
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Competition from other cell therapy companies
Opportunities
- Potential to address unmet needs in solid tumor treatment
- Expansion of TIL therapy platform to new indications
- Partnerships with larger pharmaceutical companies
- Advancements in TIL manufacturing technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- IOVA
- NK
- CRBU
Competitive Landscape
Instil Bio competes with other cell therapy companies developing treatments for cancer. Its advantages include its proprietary TIL therapy platform and focus on improving manufacturing. Disadvantages include its clinical stage and high cash burn rate.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been driven by its progress in developing TIL therapy candidates and securing funding.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its TIL therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing ITIL-168 through clinical trials, improving TIL manufacturing processes, and expanding its pipeline of TIL therapy candidates.
Summary
Instil Bio is a clinical-stage biopharmaceutical company developing TIL therapies for solid tumors. The company's success hinges on the success of its clinical trials, particularly ITIL-168. The company has a strong platform and focus on improving manufacturing but is exposed to high cash burn and fierce competition. Investors should monitor clinical trial data and regulatory developments closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Instil Bio Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-03-19 | Chairman & CEO Mr. Bronson Crouch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://instilbio.com |
Full time employees 14 | Website https://instilbio.com | ||
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.